Limits...
Access to the next wave of biologic therapies (Abatacept and Tocilizumab) for the treatment of rheumatoid arthritis in England and Wales: addressing treatment outside the current NICE guidance.

Chiu Y, Ostor AJ, Hammond A, Sokoll K, Anderson M, Buch M, Ehrenstein MR, Gordon P, Steer S, Bruce IN - Clin. Rheumatol. (2012)

Bottom Line: Specifically, we consider the use of tocilizumab or abatacept as the most appropriate treatments for some patients.At present, it is unclear the extent to which the proposed reform of the NHS will affect the role of NICE in providing guidance and setting standards of care.Until the full impact of the proposed changes are realized, individual funding requests will remain a valuable way of securing the optimal treatment for all patients suffering from RA.

View Article: PubMed Central - PubMed

Affiliation: Department of Rheumatology, Wirral University Teaching Hospital, Wirral, UK. yee.chiu@liverpool.ac.uk

ABSTRACT
Patients in England and Wales with rheumatoid arthritis (RA) receive treatment from the National Health Service (NHS) with therapies approved by the European Medicines Agency (EMA), under guidance from the National Institute for Health and Clinical Excellence (NICE). This document overviews the current NICE guidelines for the treatment of RA and identifies scenarios when such guidance may not represent the optimum management strategy for individual patients. Specifically, we consider the use of tocilizumab or abatacept as the most appropriate treatments for some patients. In such scenarios, it may be possible for the clinician to secure access to the required therapy through an application procedure known as an 'individual funding request', the process of which is described in detail here. At present, it is unclear the extent to which the proposed reform of the NHS will affect the role of NICE in providing guidance and setting standards of care. Until the full impact of the proposed changes are realized, individual funding requests will remain a valuable way of securing the optimal treatment for all patients suffering from RA.

Show MeSH

Related in: MedlinePlus

Individual funding requests. a General overview of the individual funding request process, reproduced by kind permission of the author [28]. b Checklist for applying for individual funding requests, adapted from ‘Your patient’s right to treatment’ [29]. SHA Strategic Health Authority
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3362712&req=5

Fig2: Individual funding requests. a General overview of the individual funding request process, reproduced by kind permission of the author [28]. b Checklist for applying for individual funding requests, adapted from ‘Your patient’s right to treatment’ [29]. SHA Strategic Health Authority

Mentions: The general process of applying for an individual funding request is outlined in Fig. 2a (note that details may vary across regions).Fig. 2


Access to the next wave of biologic therapies (Abatacept and Tocilizumab) for the treatment of rheumatoid arthritis in England and Wales: addressing treatment outside the current NICE guidance.

Chiu Y, Ostor AJ, Hammond A, Sokoll K, Anderson M, Buch M, Ehrenstein MR, Gordon P, Steer S, Bruce IN - Clin. Rheumatol. (2012)

Individual funding requests. a General overview of the individual funding request process, reproduced by kind permission of the author [28]. b Checklist for applying for individual funding requests, adapted from ‘Your patient’s right to treatment’ [29]. SHA Strategic Health Authority
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3362712&req=5

Fig2: Individual funding requests. a General overview of the individual funding request process, reproduced by kind permission of the author [28]. b Checklist for applying for individual funding requests, adapted from ‘Your patient’s right to treatment’ [29]. SHA Strategic Health Authority
Mentions: The general process of applying for an individual funding request is outlined in Fig. 2a (note that details may vary across regions).Fig. 2

Bottom Line: Specifically, we consider the use of tocilizumab or abatacept as the most appropriate treatments for some patients.At present, it is unclear the extent to which the proposed reform of the NHS will affect the role of NICE in providing guidance and setting standards of care.Until the full impact of the proposed changes are realized, individual funding requests will remain a valuable way of securing the optimal treatment for all patients suffering from RA.

View Article: PubMed Central - PubMed

Affiliation: Department of Rheumatology, Wirral University Teaching Hospital, Wirral, UK. yee.chiu@liverpool.ac.uk

ABSTRACT
Patients in England and Wales with rheumatoid arthritis (RA) receive treatment from the National Health Service (NHS) with therapies approved by the European Medicines Agency (EMA), under guidance from the National Institute for Health and Clinical Excellence (NICE). This document overviews the current NICE guidelines for the treatment of RA and identifies scenarios when such guidance may not represent the optimum management strategy for individual patients. Specifically, we consider the use of tocilizumab or abatacept as the most appropriate treatments for some patients. In such scenarios, it may be possible for the clinician to secure access to the required therapy through an application procedure known as an 'individual funding request', the process of which is described in detail here. At present, it is unclear the extent to which the proposed reform of the NHS will affect the role of NICE in providing guidance and setting standards of care. Until the full impact of the proposed changes are realized, individual funding requests will remain a valuable way of securing the optimal treatment for all patients suffering from RA.

Show MeSH
Related in: MedlinePlus